Real-world data show positive results for Tepezza in dysthyroid optic neuropathy
Click Here to Manage Email Alerts
Key takeaways:
- Visual acuity, clinical activity score and other measures improved in patients with dysthyroid optic neuropathy.
- Adverse events included fatigue, dysgeusia and hearing issues.
An analysis of real-world data showed that Tepezza helped improve visual acuity in patients with dysthyroid optic neuropathy, according to a press release.
“We know how devastating thyroid eye disease can be for patients, and the risk of blindness in those with dysthyroid optic neuropathy is one of the most worrisome complications, especially when traditional therapies fail,” study author Madhura A. Tamhankar, MD, said in the release. “These data are encouraging for physicians looking for an option to treat patients at the highest risk of losing their sight and provide evidence that Tepezza can help improve symptoms and preserve visual acuity.”
Image: Adobe Stock
The analysis included patients with thyroid eye disease and dysthyroid optic neuropathy (DON) who were treated with Tepezza (teprotumumab-trbw, Horizon Therapeutics) between January 2020 and September 2022. After treatment, visual acuity, proptosis, diplopia and clinical activity score improved in eyes with DON. Many of the patients had not responded to previous treatments, according to the release.
Adverse events were consistent with those seen in clinical trials of Tepezza, including fatigue, dysgeusia, hearing issues, nausea, hyperglycemia and muscle spasms.
Read more about
Click Here to Manage Email Alerts